Two Sigma Investments LP boosted its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 21.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 381,237 shares of the company's stock after buying an additional 67,134 shares during the quarter. Two Sigma Investments LP owned 0.45% of Liquidia worth $4,483,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in LQDA. LM Advisors LLC acquired a new position in Liquidia in the 4th quarter worth $25,948,000. Invesco Ltd. lifted its holdings in Liquidia by 2,675.0% in the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after buying an additional 674,940 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Liquidia by 1,484.5% in the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company's stock worth $6,293,000 after buying an additional 501,752 shares in the last quarter. Mirabella Financial Services LLP acquired a new stake in shares of Liquidia in the 4th quarter valued at about $5,880,000. Finally, Eversept Partners LP raised its stake in shares of Liquidia by 314.1% in the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company's stock valued at $6,719,000 after purchasing an additional 433,356 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.
Insider Buying and Selling at Liquidia
In other Liquidia news, insider Jason Adair sold 1,856 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the sale, the insider now owns 184,304 shares in the company, valued at approximately $2,501,005.28. This trade represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Russell Schundler sold 5,964 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $80,931.48. Following the transaction, the general counsel now owns 570,301 shares in the company, valued at $7,738,984.57. This represents a 1.03% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,138 shares of company stock worth $450,233. 26.50% of the stock is owned by company insiders.
Liquidia Trading Up 0.2%
LQDA traded up $0.03 on Friday, hitting $15.03. 1,879,582 shares of the company's stock were exchanged, compared to its average volume of 1,088,318. The firm has a market cap of $1.28 billion, a PE ratio of -9.22 and a beta of 0.24. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $19.41. The stock has a fifty day moving average of $14.71 and a two-hundred day moving average of $13.72.
Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The business had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, analysts predict that Liquidia Co. will post -1.51 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. BTIG Research restated a "buy" rating on shares of Liquidia in a research note on Tuesday. Needham & Company LLC restated a "buy" rating and issued a $25.00 target price on shares of Liquidia in a research note on Wednesday. Raymond James upped their target price on shares of Liquidia from $27.00 to $29.00 and gave the company a "strong-buy" rating in a research note on Friday, May 9th. Scotiabank upped their target price on shares of Liquidia from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday. Finally, HC Wainwright upped their target price on shares of Liquidia from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.67.
View Our Latest Report on Liquidia
About Liquidia
(
Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Recommended Stories
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
